S.R. David

2.3k total citations
28 papers, 1.8k citations indexed

About

S.R. David is a scholar working on Psychiatry and Mental health, Clinical Psychology and Pharmacology. According to data from OpenAlex, S.R. David has authored 28 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Psychiatry and Mental health, 8 papers in Clinical Psychology and 3 papers in Pharmacology. Recurrent topics in S.R. David's work include Schizophrenia research and treatment (14 papers), Electroconvulsive Therapy Studies (10 papers) and Bipolar Disorder and Treatment (9 papers). S.R. David is often cited by papers focused on Schizophrenia research and treatment (14 papers), Electroconvulsive Therapy Studies (10 papers) and Bipolar Disorder and Treatment (9 papers). S.R. David collaborates with scholars based in United States, United Kingdom and South Africa. S.R. David's co-authors include Craig Mallinckrodt, W. Scott Clark, Alan Breier, Cindy C. Taylor, Karena Meehan, Bruce J. Kinon, Mauricio Tohen, Pádraig Wright, Martin Birkett and T.M. Sanger and has published in prestigious journals such as American Journal of Psychiatry, Schizophrenia Research and Clinical Therapeutics.

In The Last Decade

S.R. David

26 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S.R. David United States 10 1.2k 560 196 145 139 28 1.8k
Steven J. Romano United States 21 798 0.6× 490 0.9× 239 1.2× 14 0.1× 69 0.5× 32 1.6k
S. Leucht Germany 11 1.7k 1.4× 555 1.0× 308 1.6× 40 0.3× 106 0.8× 19 2.2k
Mingyuan Zhang China 17 820 0.7× 359 0.6× 118 0.6× 20 0.1× 36 0.3× 55 1.8k
Arja Tuunainen Finland 18 445 0.4× 88 0.2× 146 0.7× 49 0.3× 60 0.4× 33 1.3k
J.-M. Azorin France 19 964 0.8× 298 0.5× 169 0.9× 12 0.1× 97 0.7× 71 1.3k
Rainer Schaub Germany 18 301 0.2× 170 0.3× 59 0.3× 88 0.6× 27 0.2× 31 1.1k
Virginia K. Sutton United States 19 1.4k 1.1× 445 0.8× 195 1.0× 11 0.1× 135 1.0× 35 1.7k
S Martin United Kingdom 14 693 0.6× 202 0.4× 248 1.3× 10 0.1× 81 0.6× 24 1.0k
Inmaculada Gilaberte Spain 23 1.0k 0.8× 356 0.6× 595 3.0× 12 0.1× 85 0.6× 67 1.8k
Lian Mao United States 22 826 0.7× 138 0.2× 97 0.5× 15 0.1× 71 0.5× 32 973

Countries citing papers authored by S.R. David

Since Specialization
Citations

This map shows the geographic impact of S.R. David's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S.R. David with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S.R. David more than expected).

Fields of papers citing papers by S.R. David

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S.R. David. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S.R. David. The network helps show where S.R. David may publish in the future.

Co-authorship network of co-authors of S.R. David

This figure shows the co-authorship network connecting the top 25 collaborators of S.R. David. A scholar is included among the top collaborators of S.R. David based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S.R. David. S.R. David is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
David, S.R., et al.. (2020). Bayesian CMA-ES. HAL (Le Centre pour la Communication Scientifique Directe). 2016. 203–204. 1 indexed citations
2.
David, S.R. & John W. Seaman. (2002). Hierarchical Bayesian analysis of the carryover effect in two-period crossover designs. Mathematical and Computer Modelling. 36(1-2). 129–138. 5 indexed citations
3.
Breier, Alan, Karena Meehan, Martin Birkett, et al.. (2002). A Double-blind, Placebo-Controlled Dose-Response Comparison of Intramuscular Olanzapine and Haloperidol in the Treatment of Acute Agitation in Schizophrenia. Archives of General Psychiatry. 59(5). 441–441. 207 indexed citations
4.
Wright, Pádraig, Karena Meehan, Martin Birkett, et al.. (2002). Smooth and safe transition from intramuscular to oral olanzapine. European Psychiatry. 17. 104–104. 3 indexed citations
5.
Wright, Pádraig, Martin Birkett, S.R. David, et al.. (2001). Double-Blind, Placebo-Controlled Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in the Treatment of Acute Agitation in Schizophrenia. American Journal of Psychiatry. 158(7). 1149–1151. 218 indexed citations
6.
Meehan, Karena, Fan Zhang, S.R. David, et al.. (2001). A Double-Blind, Randomized Comparison of the Efficacy and Safety of Intramuscular Injections of Olanzapine, Lorazepam, or Placebo in Treating Acutely Agitated Patients Diagnosed With Bipolar Mania. Journal of Clinical Psychopharmacology. 21(4). 389–397. 171 indexed citations
7.
David, S.R., Charles M. Beasley, & Karla Alaka. (2001). Analysis of the QTc interval in acutely agitated patients with schizophrenia, bipolar mania, or dementia treated with intramuscular (IM) olanzapine vs. IM placebo or IM haloperidol. European Neuropsychopharmacology. 11. S276–S276. 4 indexed citations
8.
Mallinckrodt, Craig, W. Scott Clark, & S.R. David. (2001). ACCOUNTING FOR DROPOUT BIAS USING MIXED-EFFECTS MODELS. Journal of Biopharmaceutical Statistics. 11(1-2). 9–21. 312 indexed citations
9.
Meehan, Karena, et al.. (2001). Intramuscular olanzapine: Efficacy and safety in acutely agitated patients with dementia. European Neuropsychopharmacology. 11. S323–S323. 1 indexed citations
10.
David, S.R., Karena Meehan, F. Zhang, et al.. (2001). Intramuscular olanzapine: Efficacy and safety in acutely agitated patients diagnosed with mania associated with bipolar disorder. European Neuropsychopharmacology. 11. S276–S277. 1 indexed citations
11.
David, S.R., Cindy C. Taylor, Bruce J. Kinon, & Alan Breier. (2000). The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clinical Therapeutics. 22(9). 1085–1096. 182 indexed citations
12.
David, S.R., Karena Meehan, Virginia K. Sutton, & Cindy C. Taylor. (2000). Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents. Schizophrenia Research. 41(1). 38–39. 6 indexed citations
13.
Meehan, Karena, S.R. David, Cindy C. Taylor, & Virginia K. Sutton. (2000). Change in extrapyramidal symptoms with olanzapine in comparison with other antipsychotic agents. Schizophrenia Research. 41(1). 192–192. 6 indexed citations
14.
Wright, Pádraig, Martin Birkett, S.R. David, et al.. (2000). A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients. European Neuropsychopharmacology. 10. 304–304. 9 indexed citations
15.
Tohen, Mauricio, T.M. Sanger, Susan L. McElroy, et al.. (1999). Olanzapine Versus Placebo in the Treatment of Acute Mania. American Journal of Psychiatry. 156(5). 702–709. 443 indexed citations
16.
David, S.R., Karena Meehan, Virginia K. Sutton, & Cindy C. Taylor. (1999). Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents. European Neuropsychopharmacology. 9. 292–292. 12 indexed citations
17.
David, S.R., A.M. Crawford, & Alan Breier. (1998). Prolactin levels in olanzapine versus typical and atypical antipsychotics. European Neuropsychopharmacology. 8. S229–S229. 8 indexed citations
18.
David, S.R., A.M. Crawford, & Alan Breier. (1998). Prolactin levels in olanzapine versus typical and atypical antipsychotics. Schizophrenia Research. 29(1-2). 153–153. 8 indexed citations
19.
Hamilton, S.H., Alan Breier, & S.R. David. (1998). Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. European Neuropsychopharmacology. 8. S228–S228. 5 indexed citations
20.
Falkai, Peter, et al.. (1991). Quantitative evaluation of astrocyte densities in schizophrenia. Schizophrenia Research. 4(3). 358–358. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven J. Romano Breakdown of academic impact, for papers by S. Leucht Breakdown of academic impact, for papers by Mingyuan Zhang Breakdown of academic impact, for papers by Arja Tuunainen Breakdown of academic impact, for papers by J.-M. Azorin Breakdown of academic impact, for papers by Rainer Schaub Breakdown of academic impact, for papers by Virginia K. Sutton Breakdown of academic impact, for papers by S Martin Breakdown of academic impact, for papers by Inmaculada Gilaberte Breakdown of academic impact, for papers by Lian Mao
Rankless by CCL
2026